Logo Image
|Articles|April 25, 2023

Discussing Challenges in mRNA Therapeutics with Phil Challis (INTERPHEX 2023)

Phil Challis, vice-president of product development at eTheRNA, discusses four of the major challenges in working with mRNA therapeutics.

Phil Challis, vice-president of product development at eTheRNA, discusses four of the major challenges in working with mRNA therapeutics. Some topics he touches on include; what makes a good RNA construct; making RNA more tolerable; storage and distribution of lipid nanoparticles; and more.

For more INTERPHEX 2023 video content, check this page for updates.

Related to this article

View more
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Read more
Trophy and confetti on light background, top view with space for text. Victory concept | Image Credit: ©New Africa -stock.adobe.com
Winners of the 2026 CPHI Pharma Awards Announced
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Read more
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Read more